Tanja Obradovic: Improved PFS versus current SOC of taxane, trastuzumab and pertuzumab
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on LinkedIn:
“Major advances for the treatment of HER2 positive breast cancer patients are here.
Amazing breakthrough after many years for the newly diagnosed or progressing from early stage disease HER2 positive metastatic breast cancer (mBC) patients as HER2-targeting ADC enhertu (trastuzumab deruxtecan, T-DXd developed by Daichi and AstraZeneca collaboration) in combination with pertuzumab (perjeta) passes interim analysis of DestinyBreast-09 trial (NCT04784715) with significantly improved PFS versus current standard of care (SOC) of taxane (docetaxel or paclitaxel), trastuzumab and pertuzumab.
Detailed results are pending including still immature OS data but PFS benefit was seen across all prespecified subgroups, suggesting activity for the wide patient population. Considering high medical need and groundbreaking new therapy option it can be expected for discussions with FDA to be rapidly ongoing.
These results in the 1st line HER2 positive mBC are energizing community to closely follow developments on two other Phase III trials of enhertu in HER2 positive breast cancer patients that are to have read outs soon this year.
Both studies are in HER2 positive early breast cancer (EBC) patients with resectable disease. DestinyBreast-11 (NCT05113251) is in the neoadjuvant setting and DestinyBreast-05 ( NCT04622319) in the adjuvant setting following neoadjuvant therapy and hold promise of delivering transformative treatment to early stage HER2 positive breast cancer disease.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023